Entering text into the input field will update the search result below

Epizyme Comeback Is Likely, Price Makes It A Buy

Mar. 30, 2021 4:14 AM ETIpsen S.A. (IPSEY)11 Comments
William Meyers profile picture
William Meyers


  • Epizyme is at a multi-year low.
  • Main cause of disappointment is slow sales of Tazverik.
  • Potential is great with label expansion and epigenetic pipeline.
DNA Technology
Photo by BlackJack3D/E+ via Getty Images

Epizyme (NASDAQ:EPZM) has been a commercial-stage pharmaceutical company for over a year now, following the FDA approval of Tazverik (tazemetostat) for treating epithelioid sarcoma in January 2020. On March 22, 2021, it fell under $8.00 per share for the first time since late 2018, despite going over $25.00 per

This article was written by

William Meyers profile picture
I provided stock and bond research and analysis to a small cap specialist investor, Lloyd Miller, from 2002 until his death in January 2018. For my own account I invest mainly in technology and biotechnology stocks. My technology and investment web site is openicon.com, where readers can view the notes I take to make decisions and to write articles for Seeking Alpha.

Analyst’s Disclosure: I am/we are long EPZM. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

I first bought EPZM in 2015 and added to my position on 3/26/2021. I will not trade in the stock over the next 72 hours.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.